2024-11-06
Cutting edge Seminar
Speaker: Kazufumi Honda (Professor, Department of Bioregulation, Graduate School of Medicine, Nippon Medical School)
Title: Liquid biomarkers for early diagnosis and risk stratification of refractory cancers, from exploratory research to clinical implementation, focusing on the tumor organ environment.
Date&Time: 6 Nov. (Wed.) 2024, 12:00- 13:00
※This seminar can also be attended through ZOOM. Please check the URL on “HIGO Cutting-Edge Seminar” at Moodle.
https://md.kumamoto-u.ac.jp/course/view.php?id=114380
Abstract:
Recently, liquid biopsy, which diagnoses cancer using trace amounts of proteins, sugar chains, metabolites, cellular vesicles, and nucleic acids shed by tumor cells, has attracted attention. In the United States, Multi-Cancer Early Detection (MCED), which uses multiplex measurement of specific modification states of biological substances present in the blood to diagnose cancer from trace amounts of blood, is being introduced to the community.
On the other hand, looking at the history of clinical implementation of cancer blood biomarkers developed in Japan, the focus is on “organ environment assessment biomarkers” that do not leak from tumor cells, such as “pepsinogen”, a marker of gastric mucosal atrophy, “M2BPGi”, a blood biomarker of liver fibrosis, and “apoA2 isoform (apoA2-i)”, a marker for pancreatic cancer diagnosis by evaluating pancreatic function.
We have identified changes in circulating apoA2-i not only in early-stage pancreatic cancer patients, but also in high-risk individuals from basic research. We redesigned the ELISA kit to measure apoA2-i, and then the apoA2-i ELISA kit was approved by the Japanese government for IVD as a biomarker to aid in the diagnosis of pancreatic cancer.
In this seminar, which focuses on the organ carcinogenesis environment, the presentation will cover the discovery and clinical implementation of liquid biomarkers for early diagnosis and risk stratification of refractory cancers.
On the other hand, looking at the history of clinical implementation of cancer blood biomarkers developed in Japan, the focus is on “organ environment assessment biomarkers” that do not leak from tumor cells, such as “pepsinogen”, a marker of gastric mucosal atrophy, “M2BPGi”, a blood biomarker of liver fibrosis, and “apoA2 isoform (apoA2-i)”, a marker for pancreatic cancer diagnosis by evaluating pancreatic function.
We have identified changes in circulating apoA2-i not only in early-stage pancreatic cancer patients, but also in high-risk individuals from basic research. We redesigned the ELISA kit to measure apoA2-i, and then the apoA2-i ELISA kit was approved by the Japanese government for IVD as a biomarker to aid in the diagnosis of pancreatic cancer.
In this seminar, which focuses on the organ carcinogenesis environment, the presentation will cover the discovery and clinical implementation of liquid biomarkers for early diagnosis and risk stratification of refractory cancers.
